252eP Temozolomide–irinotecan (TEMIRI) protocol in adult patients with relapsed/refractory Ewing sarcoma: A single-center experience

ESMO rare cancers. 2026 Open access

Read full text
Authors: B. Zivkovic, V. Lukic, D.A. Djurdjevic, J. Mijucic, Dusanka Ristic
DOI: 10.1016/j.esmorc.2026.100458
Cited by: 0

Abstract

The TEMIRI chemotherapy regimen is considered a standard of care for relapsed or refractory Ewing sarcoma. However, clinical experience with this regimen in adult patients remains limited due to lack of clinical data.

Fields of Study & Subjects

Sarcoma Diagnosis and Treatment Acute Lymphoblastic Leukemia research PARP inhibition in cancer therapy

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100458–100458
Publication date
1 March 2026
Language
EN